Cancer Research and Treatment

Original Articles

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer: Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi; Cancer Res Treat. 2011;43(1):32-41. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.32

PURPOSE
To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation.
MATERIALS AND METHODS
From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy).
RESULTS
Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23 complete responses. The median survival duration for the overall patient group was 17.6 months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007), and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively.
CONCLUSION
Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required.

Citations

Citations to this article as recorded by

A scoping review on population-centered indicators for cancer care continuum
Vasuki Rajaguru, Jieun Jang, Jeoung A. Kwon, Jae Hyun Kim, Jaeyong Shin, Mison Chun
Frontiers in Public Health.2022;[Epub] CrossRef
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
Lipin Liu, Nan Bi, Zhe Ji, Junling Li, Jingbo Wang, Xiaozhen Wang, Zhouguang Hui, Jima Lv, Jun Liang, Zongmei Zhou, Yan Wang, Weibo Yin, Luhua Wang
BMC Cancer.2015;[Epub] CrossRef
Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
Jian L. Campian, Xiaobu Ye, Malcolm Brock, Stuart A. Grossman
Cancer Investigation.2013; 31(3): 183. CrossRef
Does Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer?
Asad A. Shah, Mathias Worni, Christopher R. Kelsey, Mark W. Onaitis, Thomas A. D'Amico, Mark F. Berry
The Annals of Thoracic Surgery.2013; 95(5): 1700. CrossRef
Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
Gangjun Du, Yingming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang
Cancer Chemotherapy and Pharmacology.2013; 71(4): 893. CrossRef

11,222 View
67 Download
5 Crossref

Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea: Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(4):155-163. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.155

Abstract PDF PubReader ePub

Purpose

This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials and Methods

One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results

One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions

This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citations

Citations to this article as recorded by

Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
Cellular Signalling.2023; 101: 110530. CrossRef
SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
Medicine.2023; 102(50): e36583. CrossRef
MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
BMC Molecular and Cell Biology.2022;[Epub] CrossRef
Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
Oral Oncology.2022; 134: 106139. CrossRef
Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating LINC01160
Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
Future Oncology.2021; 17(1): 57. CrossRef
RETRACTED ARTICLE: Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
Cellular & Molecular Biology Letters.2021;[Epub] CrossRef
DNA methylation biomarkers for nasopharyngeal carcinoma
Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
PLOS ONE.2020; 15(4): e0230524. CrossRef
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
Biomedicine & Pharmacotherapy.2018; 106: 217. CrossRef
Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
Oncotarget.2018; 9(2): 1843. CrossRef
GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
Tumor Biology.2016; 37(4): 4559. CrossRef
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
Cancer Research and Treatment.2016; 48(3): 917. CrossRef
MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145. CrossRef
Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
Tumor Biology.2015; 36(9): 6679. CrossRef
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142. CrossRef
MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
Experimental Cell Research.2015;[Epub] CrossRef
miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
Cell Biochemistry and Function.2015; 33(8): 534. CrossRef
Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef
MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
FEBS Letters.2014; 588(20): 3732. CrossRef
IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
Japanese Journal of Clinical Oncology.2012; 42(12): 1152. CrossRef
Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
Acta Oto-Laryngologica.2011; 131(8): 852. CrossRef
miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
Biochemical and Biophysical Research Communications.2010; 391(1): 535. CrossRef

10,963 View
67 Download
22 Crossref

The Effect of Simulation on Recurrence after Breast-Conserving Surgery and Radiotherapy: Preliminary Results: Ji-Yoon Kim, Yeon-Sil Kim, Mi-Ryung Ryu, Sung-Whan Kim, Chul-Seung Kay, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung; Cancer Res Treat. 2006;38(1):40-47. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.40

Abstract PDF PubReader ePub: Purpose
To evaluate the effect of the simulation method on recurrence among the patients who received radiotherapy after breast-conserving surgery (BCS) for early breast carcinoma.
Materials and Methods
Between 1995 and 2000, 70 patients with stage I-II breast carcinoma underwent breast-conserving surgery and adjuvant radiotherapy. Twenty nine patients (41.4%) were simulated with the 2D contour-based method (September 1995 to August 1997) and 41 patients (58.6%) were simulated with the 3D CT-based method (September 1997 to February 2000). To analyze the effect of the simulation method, the patient and treatment characteristics were compared.
Results
The characteristics were similar for the patients between the 2D contour-based simulation group and the 3D CT-based simulation group. During a median follow-up period of 75 months, 4 (13.8%) of 29 patients who were treated with 2D simulation and 1 (2.4%) of 41 patients who were treated with 3D simulation group developed treatment failure. The five-year survival rates were 89.2% and 95.1% between the 2D and 3D simulation groups (p=0.196). The five-year disease free survival (DFS) rates were 86.2% and 97.5% between the 2D and 3D simulation groups (p=0.0636). On univariate analysis, age > 40 (p= 0.0226) and the number of dissected axillary lymph node ≥ 10 (p=0.0435) were independent predictors of improved 5-year DFS.
Conclusions
Although our data showed marginal significance for the DFS between the two groups, it is insufficient, due to the small number of patients in our study, to prove whether 3D CT-based simulation might improve the DFS and reduce the risk of recurrence when compared with 2D contour-based simulation. Further study is needed with a larger group of patients.

11,432 View
46 Download

Case Report

The Role of Radiation Therapy for the Extramammary Paget's Disease of the Vulva ; Experience of 3 Cases: Seok-Hyun Son, Jung-Seok Lee, Yeon-Sil Kim, Mi-Ryeong Ryu, Su-Mi Chung, Sung-Eun Namkoong, Gu-Taek Han, Hee-Jeong Lee, Sei-Chul Yoon; Cancer Res Treat. 2005;37(6):365-369. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.365

Abstract PDF PubReader ePub

We have experienced three cases of extramammary Paget's disease (EMPD) of the vulva that received radiation therapy (RT). Here, we analyze the efficacy of RT and include a literature survey.

Three patients with EMPD of the vulva were treated with curative RT between 1993 and 1998. One of the patients had associated underlying adenocarcinoma of the vulva. The total doses of radiation administered were 54~78 Gy/6~8 weeks. Radiation fields encompassed 2 to 3 cm outer margins free from all visible disease including or not including the inguinal area using a 9 MeV electron or a 6 MV photon beam. Follow-up durations after radiotherapy were 0.6~11 years. Complete response was obtained in all three patients. Marginal failure occurred in one patient, and another patient with underlying adenocarcinoma treated by vulvectomy with bilateral inguinal lymph node dissection followed by external RT showed no relapse. Radiation induced side effects were transient acute confluent wet desquamation in the treated area resulting in mild late atrophic skin changes.

Although surgery is currently considered the preferred primary treatment for EMPD, it has a high relapse rate due to the multifocal nature of the disease. We conclude that RT is of benefit in some selected cases of EMPD.

Citations

Citations to this article as recorded by

Anatomic Subtype Differences in Extramammary Paget Disease
Nour Kibbi, Joshua L. Owen, Brandon Worley, Jake X. Wang, Vishnu Harikumar, Sumaira Z. Aasi, Sunandana Chandra, Jennifer N. Choi, Yasuhiro Fujisawa, Christos Iavazzo, John Y. S. Kim, Naomi Lawrence, Mario M. Leitao, Allan B. MacLean, Jeffrey S. Ross, Anth
JAMA Dermatology.2024; 160(4): 417. CrossRef
Vulvar Paget Disease: a series of cases in southern Brazil
Marcella B. Persiano, Elisa T. Rosin, Giovana A. Cabrera, Fernanda Uratani, Leticia V. Pires, Felipe Luzzatto, Kathleen M. Schmeler, Mila P. Salcedo
Journal of Global Health Reports.2023;[Epub] CrossRef
The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease
Michelle van der Linden, Colette L. van Hees, Marc van Beurden, Johan Bulten, Eleonora B. van Dorst, Martha D. Esajas, Kim A. Meeuwis, Dorry Boll, Mariëtte I. van Poelgeest, Joanne A. de Hullu
American Journal of Obstetrics and Gynecology.2022; 227(2): 250.e1. CrossRef
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the Vulva
Marina Stasenko, Gowtham Jayakumaran, Renee Cowan, Vance Broach, Dennis S. Chi, Anthony Rossi, Travis J. Hollman, Ahmet Zehir, Nadeem R. Abu-Rustum, Mario M. Leitao
JCO Precision Oncology.2020; (4): 1054. CrossRef
Invasive Vulval Paget’s disease treated with primary radiotherapy: A rare case report and literature review
Avir Sarkar, S.C. Saha, Pooja Sikka, Neha Kumari, Pranab Dey, Bhavana Rai
Gynecologic Oncology Reports.2020; 34: 100674. CrossRef
Nonsurgical Treatments for Extramammary Paget Disease: A Systematic Review and Meta-Analysis
Igor Snast, Eran Sharon, Ran Kaftory, Yehonatan Noyman, Meital Oren-Shabtai, Moshe Lapidoth, Emmilia Hodak, Daniel Mimouni, Sigal Mazor, Assi Levi
Dermatology.2020; 236(6): 493. CrossRef
A Rare Case of Recurrent Paget’s Disease of the Vulva and Gluteal Region Treated with Radiation Therapy
Mirza Athar Ali, M. Babaiah, Prabhakar Mariappan, Sudha Sinha, KR Muralidhar, Srinivas Ponaganti, Pranav Ashwin Shah, Sujana Priya Vuba, Arun Kumar Reddy Gorla, Deepak Koppaka
Applied Radiation Oncology.2020; : 44. CrossRef
Efficacy of low‐dose 5‐fluorouracil/cisplatin therapy for invasive extramammary Paget's disease
Hiroshi Kato, Shoichi Watanabe, Kiyonori Kariya, Motoki NAKAMURA, Akimichi Morita
The Journal of Dermatology.2018; 45(5): 560. CrossRef
The Role of Radiotherapy in Extramammary Paget Disease
L. Tagliaferri, C. Castà, G. Macchia, A. Pesce, G. Garganese, B. Gui, G. Perotti, S. Gentileschi, F. Inzani, R. Autorino, S. Cammelli, A.G. Morganti, V. Valentini, M.A. Gambacorta
International Journal of Gynecological Cancer.2018; 28(4): 829. CrossRef
The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease
Michelle van der Linden, Kim Meeuwis, Colette van Hees, Eleonora van Dorst, Johan Bulten, Tjalling Bosse, Joanna IntHout, Dorry Boll, Brigitte Slangen, Manon van Seters, Marc van Beurden, Mariëtte van Poelgeest, Joanne de Hullu
JMIR Research Protocols.2017; 6(9): e178. CrossRef
Paget disease of the vulva
M. van der Linden, K.A.P. Meeuwis, J. Bulten, T. Bosse, M.I.E. van Poelgeest, J.A. de Hullu
Critical Reviews in Oncology/Hematology.2016; 101: 60. CrossRef
Primary extramammary invasive Paget’s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy?
Maria Tolia, Nikolaos Tsoukalas, Chrisostomos Sofoudis, Constantinos Giaginis, Despoina Spyropoulou, Dimitrios Kardamakis, Vasileios Kouloulias, George Kyrgias
BMC Cancer.2016;[Epub] CrossRef
Extramammary Paget Disease of the Vulva: Minimal Excision with Adjuvant Radiation Treatment for Optimal Aesthetic Results
Myeong Su Jeon, Gyu Yong Jung, Joon Ho Lee, Kyung Won Kang, Kwang Won No
Tumori Journal.2016; 102(2_suppl): S84. CrossRef
Paget Disease of the Vulva: Diagnosis by Immunohistochemistry
Andressa Gonçalves Amorim, Brunelle Batista Fraga Mendes, Rodrigo Neves Ferreira, Antônio Chambô Filho
Case Reports in Dermatological Medicine.2015; 2015: 1. CrossRef
Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors
M. Hata, I. Koike, H. Wada, E. Miyagi, T. Kasuya, H. Kaizu, T. Matsui, Y. Mukai, E. Ito, T. Inoue
Annals of Oncology.2014; 25(1): 291. CrossRef
Radiotherapy in Patients with Extramammary Paget's Disease - Our Own Experience and Review of the Literature
Tomohiro Itonaga, Hidetsugu Nakayama, Mitsuru Okubo, Ryuji Mikami, Sachica Nogi, Yu Tajima, Shinji Sugahara, Koichi Tokuuye
Oncology Research and Treatment.2014; 37(1-2): 18. CrossRef
Extramammary Paget's Disease of the Vulva: A Case Report and Review of the Literature
Nirmala Duhan, Mansi Juneja, Sunita Singh
Journal of Gynecologic Surgery.2013; 29(6): 297. CrossRef
HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease
Soraya Marcos, Angel Montero, Belén Capuz, Javier Martinez-Ollero, Raúl Hernanz, Eva Fernández, Alfredo Polo, Alfredo Ramos
Reports of Practical Oncology & Radiotherapy.2012; 17(3): 163. CrossRef
Extramammary Paget's disease treated with topical imiquimod 5% cream
Sue-Ann J. E. Ho, Derrick C. W. Aw
Dermatologic Therapy.2010; 23(4): 423. CrossRef

13,507 View
134 Download
19 Crossref

Original Article

Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report: Ji-Young Jang, Mi-Ryeong Ryu, Sung-Whan Kim, Chul-Seung Kay, Yeon-Sil Kim, Yoon-Kyeong Oh, Hyung-Chul Kwon, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung; Cancer Res Treat. 2005;37(6):344-348. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.344

Abstract PDF PubReader ePub: Purpose
Breast-conserving therapy (BCT) is a practical alternative to mastectomy for treating ductal carcinoma in situ (DCIS). We reviewed our experience for treating patients with DCIS of the breast to evaluate the outcome after performing breast-conserving surgery plus radiotherapy (BCS-RT).
Materials and Methods
Between January 1983 and December 2002, 25 patients with clinically or mammographically detected DCIS were treated by BCS-RT. One patient was diagnosed with bilateral DCIS. Thirteen cases (50%) had symptomatic lesions at presentation. All 26 cases of 25 patients underwent BCS such as lumpectomy, partial mastectomy or quadrantectomy. All of them received whole breast irradiation to a median dose of 50.4 Gy. Twenty-four cases (92.3%) received a boost to the tumor bed for a median total dose of 59.4 Gy. The median follow up period was 67 months (range: 38 to 149 months).
Results
Two cases (7.7%) experienced ipsilateral breast tumor recurrence (IBTR) after BCS-RT. The histology results at the time of IBTR showed invasive ductal carcinoma (IDC), and the median time to IBTR was 25.5 months. On the univariate analysis, there were no significant factors associated with IBTR in the DCIS patients. The three-year local recurrence free survival rate was 96.0% and the overall survival rate was 96.3%.
Conclusion
After the treatment for DCIS, the IBTR rate in our study was similar to other previous studies. Considering that we included patients who had many symptomatic lesions, close or positive margins and less that complete early data, our result is comparable to the previous studies. We could not find the prognostic significant factors associated with IBTR after BCS-RT. A longer follow up period with more patients would be required to evaluate the role of any predictive factors and to confirm these short-term results.

8,504 View
56 Download

First
Prev
Page of 1
Next
Last

Search